Have a feature idea you'd love to see implemented? Let us know!

NEO Neogenomics Inc

Price (delayed)

$18.36

Market cap

$2.36B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.61

Enterprise value

$2.6B

NeoGenomics, Inc. specializes in cancer genetics testing and information services. The Company provides one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose ...

Highlights
The company's EPS rose by 21% YoY
Neogenomics's gross profit has increased by 20% YoY and by 4.7% QoQ
The quick ratio has plunged by 68% YoY
The equity is down by 4.1% year-on-year

Key stats

What are the main financial stats of NEO
Market
Shares outstanding
128.36M
Market cap
$2.36B
Enterprise value
$2.6B
Valuations
Price to book (P/B)
2.59
Price to sales (P/S)
3.62
EV/EBIT
N/A
EV/EBITDA
123.77
EV/Sales
4.04
Earnings
Revenue
$644.12M
Gross profit
$280.43M
Net income
-$77.73M
EBIT
-$61.1M
EBITDA
$21.02M
Free cash flow
-$21.51M
Per share
EPS
-$0.61
EPS diluted
-$0.61
Free cash flow per share
-$0.17
Book value per share
$7.09
Revenue per share
$5.07
TBVPS
$6.07
Balance sheet
Total assets
$1.64B
Total liabilities
$732.9M
Debt
$606.27M
Equity
$908.21M
Working capital
$293.84M
Liquidity
Debt to equity
0.67
Current ratio
1.99
Quick ratio
1.82
Net debt/EBITDA
11.62
Margins
EBITDA margin
3.3%
Gross margin
43.5%
Net margin
-12.1%
Operating margin
-14.3%
Efficiency
Return on assets
-4.7%
Return on equity
-8.4%
Return on invested capital
-7.3%
Return on capital employed
-4.5%
Return on sales
-9.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NEO stock price

How has the Neogenomics stock price performed over time
Intraday
3.79%
1 week
11.41%
1 month
3.38%
1 year
17.62%
YTD
11.41%
QTD
11.41%

Financial performance

How have Neogenomics's revenue and profit performed over time
Revenue
$644.12M
Gross profit
$280.43M
Operating income
-$92.28M
Net income
-$77.73M
Gross margin
43.5%
Net margin
-12.1%
NEO financials
Neogenomics's operating margin has increased by 29% YoY and by 6% from the previous quarter
NEO's net margin is up by 28% YoY and by 3.2% QoQ
The company's operating income rose by 20% YoY and by 3.1% QoQ
Neogenomics's gross profit has increased by 20% YoY and by 4.7% QoQ

Growth

What is Neogenomics's growth rate over time
NEO growth chart

Valuation

What is Neogenomics stock price valuation
P/E
N/A
P/B
2.59
P/S
3.62
EV/EBIT
N/A
EV/EBITDA
123.77
EV/Sales
4.04
Price to earnings (P/E)
The company's EPS rose by 21% YoY
Price to book (P/B)
The price to book (P/B) is 26% less than the 5-year quarterly average of 3.4 but 19% more than the last 4 quarters average of 2.1
The equity is down by 4.1% year-on-year
Price to sales (P/S)
The price to sales (P/S) is 42% lower than the 5-year quarterly average of 6.0 but 13% higher than the last 4 quarters average of 3.1
The revenue rose by 12% YoY and by 2.5% QoQ

Efficiency

How efficient is Neogenomics business performance
The company's return on sales rose by 44% YoY and by 8% QoQ
NEO's ROIC is up by 23% year-on-year
The return on assets rose by 16% year-on-year
The return on equity has increased by 15% year-on-year

Dividends

What is NEO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NEO.

Financial health

How did Neogenomics financials performed over time
Assets vs liabilities
The total assets is 124% greater than the total liabilities
NEO's current ratio has plunged by 69% YoY
The quick ratio has plunged by 68% YoY
Debt vs equity
NEO's debt is 33% lower than its equity
The debt to equity rose by 4.7% year-on-year
The equity is down by 4.1% year-on-year
Balance sheet

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.